Clinical Trials Browser

Phase 2 × Immunoglobulin G × Sarcoma × Clear all

NCT00977574 2025-10-31

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04668300 2025-10-09

DOSa

Phase 2 Active not recruiting

Hemangiosarcoma, Liposarcoma, Osteosarcoma

NCT03141684 2025-10-08

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Phase 2 Active not recruiting

63 enrolled 1 FDA

Sarcoma, Alveolar Soft Part

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Phase 2 Recruiting

Leiomyosarcoma, Sarcoma

NCT03623854 2024-04-16

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Phase 2 Completed

Chordoma

NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Phase 2 Completed

137 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00433381 2018-09-17

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Phase 2 Completed

123 enrolled 16 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01222715 2017-05-05

Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Phase 2 Completed

87 enrolled 11 charts

Rhabdomyosarcoma, Sarcoma